Inactive Instrument

Jerusalem Pharmaceutical Co. Stock price Palestine Exchange

Equities

Pharmaceuticals

End-of-day quote Palestine Exchange
- 0.00% Intraday chart for Jerusalem Pharmaceutical Co.
Sales 2021 46.23M 0 Sales 2022 46.14M 0 Capitalization 59.04M 0
Net income 2021 6M - Net income 2022 7M - EV / Sales 2021 1.04 x
Net cash position 2021 2.86M 0 Net cash position 2022 5.6M 0 EV / Sales 2022 1.16 x
P/E ratio 2021
7.72 x
P/E ratio 2022
8.23 x
Employees -
Yield 2021
4.24%
Yield 2022
4.57%
Free-Float 36%
More Fundamentals * Assessed data
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Jerusalem Pharmaceuticals Co. Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019 CI
Jerusalem Pharmaceuticals Co. Ltd. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2018 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Consolidated Unaudited Earnings Results for the Year Ended December 31, 2018 CI
Jerusalem Pharmaceuticals Co. Ltd. Reports Unaudited Earnings Results for the Nine Months Ended September 30, 2018 CI
More news
Managers TitleAgeSince
Chief Executive Officer - 13-06-30
Director of Finance/CFO - 20-02-29
Chief Tech/Sci/R&D Officer - 88-12-31
Members of the board TitleAgeSince
Chairman 89 -
Director/Board Member - -
Director/Board Member - -
More insiders
Jerusalem Pharmaceuticals Co Ltd (Al-Quds) is a Palestine-based public shareholding company engaged in the manufacture and trade of pharmaceutical, veterinary, detergent, and cosmetics products. Its product range spans the whole spectrum of ethical pharmaceuticals, as well as over the counter preparations and nutritional supplements. Its Products are presented in different dosage forms such as tablets, capsules, ampoules, granules and powders for suspensions, suspensions, syrups, lotions, powders, suppositories, ovules, creams, ointments, gels, emulgels, ear, eye and nose drops, solutions, mouth rinse and gargles. The Company also produces veterinary products including vials, powders, oral liquids and fodder additives such as multivitamins and multi-minerals. It also manufactures detergents and cosmetics under license from French companies. The Company operates three production facilities include Factory for General Production, Penicillin Factory and Cephalosporin Factory.
More about the company
  1. Stock
  2. Equities
  3. Stock Jerusalem Pharmaceuticals Co. Ltd.
  4. Stock Jerusalem Pharmaceutical Co. - Palestine Exchange